$12.84
-0.37-2.8%
At close: Sep 2, 5:00 PM EST
$12.90
0.060.47%
After Hours: 7:57 PM EST
Defiance Daily Target 2x Long MSTR ETF Stock News
MSTXNASDAQ
Latest Defiance Daily Target 2x Long MSTR ETF News | NASDAQ:MSTX | Benzinga
Get the latest news on Defiance Daily Target 2x Long MSTR ETF stock with updates on market trends, financials, and analysis from Benzinga. Stay informed on Defiance Daily Target 2x Long MSTR ETF performance
Categories: All
Thursday, March 19, 2026
Wednesday, March 18, 2026
Monday, February 02, 2026
Tuesday, December 02, 2025
Thursday, September 25, 2025
Friday, May 02, 2025
Friday, March 14, 2025
Monday, March 10, 2025
Thursday, February 13, 2025
Tuesday, December 31, 2024
Friday, December 27, 2024
Tuesday, December 24, 2024
Thursday, December 05, 2024
Wednesday, November 27, 2024
Thursday, November 21, 2024
Wednesday, September 18, 2024
Thursday, August 22, 2024
Thursday, April 20, 2017
Monday, April 17, 2017
Tuesday, April 11, 2017
Monday, March 06, 2017
Monday, January 09, 2017
Saturday, January 07, 2017
Tuesday, December 06, 2016
Tuesday, November 08, 2016
Monday, October 17, 2016
Tuesday, September 27, 2016
Monday, September 26, 2016
Wednesday, September 21, 2016
- Mid-Afternoon Market Update: Dow Surges 125 Points; FedEx Shares Jump Following Upbeat Earnings
- 12 Biggest Mid-Day Losers For Wednesday
- Mid-Day Market Update: Crude Oil Up 2.75%; Mast Therapeutics Shares Drop After Sickle Cell Drug Phase 3 Trial Fail
- Mid-Morning Market Update: Markets Open Higher; General Mills Earnings Top Views
- 20 Stocks Moving In Wednesday's Pre-Market Session
Tuesday, September 20, 2016
- After-Hours Decliners Sept. 20, 2016: MSTX Down 84%, MIRN 29%, BMRN 1%
- Shkreli Warned You: Mast Therapeutics Plummets 80% After Sickle Cell Drug Phase 3 Trial Fail
- Mast Therapeutics Shares Down 80% in After-Hours Action
- UPDATE: Mast Expects To Terminate All Clinical Development Of vepoloxamer, Intends To Reduce Operating Expenses Immediately
- Mast Therapeutics Reports Top-Line Results From Phase 3 Study In Sickle Cell Disease, Did Not Meet Primary Endpoint
